News coverage about Cepheid (NASDAQ:CPHD) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cepheid earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news articles about the scientific and technical instruments company an impact score of 49.276878283802 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Cepheid (NASDAQ CPHD) remained flat at $52.95 during trading on Friday. The stock’s 50-day moving average price is $52.75 and its 200 day moving average price is $38.36. Cepheid has a 52 week low of $25.09 and a 52 week high of $53.91.
WARNING: This piece was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/08/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-cepheid-nasdaqcphd-stock-price-updated.html.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.
